Skip to content

Clinical application of new imaging agent Al [18F]-FAPI-04 in tumor

Clinical application of new imaging agent Al [18F]-FAPI-04 in tumor

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048334
Enrollment
Unknown
Registered
2021-07-05
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor

Interventions

Gold Standard:Confirmed by surgery or biopsy pathology.
&#32
uptake
ingestion&#32
minimum
Tumor&#32

Sponsors

PET-CT Center, Affiliated Cancer Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Adult participants (aged 18 years or order); 2.Participants with newly diagnosed tumor; 3.Participants who had scheduled both 18F-FDG and 18F-FAPI PET/CT scans; 4.Participants who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

Exclusion criteria: 1.Participants with non-malignant lesions; 2.Participants with pregnancy; 3.Treatment has already started between the 2 PET scans.

Design outcomes

Primary

MeasureTime frame
Standard uptake value;Standard uptake value max;Standard uptake value mean;Standard uptake value minimum;Metabolic tumor volume;total lesion glycolysis;

Countries

China

Contacts

Public ContactLi Peng

Affiliated Cancer Hospital of Zhengzhou University

65440762@qq.com+86 13663867638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026